Multicenter trial with ubidecarenone: Treatment of 44 patients with mitochondrial myopathies

G. Scarlato, N. Bresolin, I. Moroni, C. Doriguzzi, E. Castelli, G. Comi, C. Angelini, A. Carenzi

Research output: Contribution to journalArticlepeer-review


Fourty four patients with mitochondrial myopathies were treated with Ubidecarenone (CoQ10) for six months in an open multicentric trial. No side effects due to the drug administration were observed. Sixteen patients showing at least 25% decrease of post exercise lactate levels were selected as responders. Responsiveness was apparently not related to CoQ10 level in serum and platelets or to the presence or absence of mtDNA deletions. The responders were further treated for 3 months with CoQ10 or placebo in the second blind part of the trial; no significant differences between the 2 groups were obsered. It is not clear why CoQ10 had therapeutic effects in some patients and not in others with the same clinical presentation and biochemical defect, and we failed to identify candidate responders before treatment. At the dosage of CoQ10 used in the study (2 mg/kg/day) the therapy requires long administration time before a response is demonstrable.

Original languageEnglish
Pages (from-to)542-548
Number of pages7
JournalRevue Neurologique
Issue number6-7
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)


Dive into the research topics of 'Multicenter trial with ubidecarenone: Treatment of 44 patients with mitochondrial myopathies'. Together they form a unique fingerprint.

Cite this